Schultz Exits: Pressures From Inside And Out Catch Up With CDRH Director
This article was originally published in The Gray Sheet
Executive Summary
At least a handful of disgruntled employees, members of Congress champing at the bit and a new reformist FDA administration were apparently the undoing of Dan Schultz's leadership of CDRH
You may also be interested in...
Retiring Rep. Dingell’s Health Policy Legacy Includes Fierce Oversight Of Device Center
A powerful former Chairman of the House Energy and Commerce Committee, Dingell has been not only a major player in the health care reform fight, but also a vigorous prober of FDA, launching investigations with lasting effects on the device center. The longest-serving member of the House announced his plans to retire at the end of this congressional term.
Retiring Rep. Dingell’s Health Policy Legacy Included Fierce Oversight Of Device Center
A powerful former Chairman of the House Energy and Commerce Committee, Dingell has not been only a major player in the health care reform fight, but also a vigorous prober of FDA, launching investigations with lasting effects on the device center. The longest-serving member of the House announced his plans to retire at the end of this congressional term.
Director Of 510(k) Pre-Market Notification Staff Makes Her Exit
Heather Rosecrans, the long-time head of the 510(k) pre-market review section at FDA's device center, says it's time for her to move on